Boehringer Ingelheim today announced new data from two trials presented at the European Respiratory Society (ERS) International Congress 2015. A posthoc analysis from OTEMTO® 1&2 indicates that ...

A post-hoc analysis from OTEMTO ® 1&2 indicates that Spiolto ® Respimat ® provides significant quality of life improvements over Spiriva ® Respimat ® (tiotropium) or placebo, right from the initial ...

INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced regulatory authority approvals for Spiolto ® Respimat ® (tiotropium/olodaterol) in first ...

Further data from the 1,600 patient OTEMTO® trials show Spiolto® Respimat® provides: clinically meaningful improvements in breathlessness compared to placebo (measured by a 1.62 point improvement in ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. Spiolto Respimat contains the active ingredients tiotropium (as ...

Boehringer Ingelheim today announced new data from two trials presented at the European Respiratory Society (ERS) International Congress 2015. A post-hoc analysis from OTEMTO ® 1&2 indicates that ...

Boehringer Ingelheim today announced the presentation of several new post-hoc analyses from the TONADO® 1&2 and OTEMTO® 1&2 studies at the American College of CHEST Physicians Annual Meeting in ...

Spiolto® Respimat® is built on tiotropium, the active ingredient in Spiriva®, enhanced by olodaterol Spiolto® Respimat® provides significant improvements in lung function, COPD symptoms, quality of ...

OTEMTO® trials show Spiolto® Respimat® provides clinically meaningful >4 point reduction in SGRQ score compared to placebo1These results demonstrate that Spiolto® Respimat® can bring noticeable ...

Thu, July 2, 2015 at 4:52 PM UTC ...

Boehringer Ingelheim today announced the publication of new data from the Phase IIIb OTEMTO ® 1&2 trials (NCT01964352/NCT02006732), which show Spiolto ® Respimat ...

Spiolto ® Respimat ® is built on tiotropium, the active ingredient in Spiriva ® – the world’s most prescribed COPD maintenance treatment with over 40 million patient years of real life experience ...